We’ve recently updated our valuation analysis.

Seagen Valuation

Is SGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SGEN?

Other financial metrics that can be useful for relative valuation.

SGEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.4x
Enterprise Value/EBITDA-37.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SGEN's PS Ratio compare to its peers?

The above table shows the PS ratio for SGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average6.9x
INCY Incyte
5.2x12.8%US$17.4b
BMRN BioMarin Pharmaceutical
9x18.6%US$18.0b
HZNP Horizon Therapeutics
4.8x10.4%US$17.7b
NBIX Neurocrine Biosciences
8.5x15.1%US$11.7b
SGEN Seagen
12.3x28.6%US$22.9b

Price-To-Sales vs Peers: SGEN is expensive based on its Price-To-Sales Ratio (12.3x) compared to the peer average (6.9x).


Price to Earnings Ratio vs Industry

How does SGEN's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.4%
n/an/an/a

Price-To-Sales vs Industry: SGEN is expensive based on its Price-To-Sales Ratio (12.3x) compared to the US Biotechs industry average (11.8x)


Price to Sales Ratio vs Fair Ratio

What is SGEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SGEN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.3x
Fair PS Ratio5.2x

Price-To-Sales vs Fair Ratio: SGEN is expensive based on its Price-To-Sales Ratio (12.3x) compared to the estimated Fair Price-To-Sales Ratio (5.2x).


Share Price vs Fair Value

What is the Fair Price of SGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SGEN ($123.44) is trading below our estimate of fair value ($249.18)

Significantly Below Fair Value: SGEN is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SGEN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$123.44
US$165.86
+34.4%
12.8%US$213.00US$135.00n/a21
Nov ’23US$126.69
US$168.76
+33.2%
12.4%US$213.00US$136.00n/a21
Oct ’23US$136.83
US$183.43
+34.1%
10.6%US$220.00US$150.00n/a21
Sep ’23US$155.96
US$183.05
+17.4%
10.9%US$220.00US$150.00n/a21
Aug ’23US$175.47
US$183.43
+4.5%
10.8%US$220.00US$150.00n/a21
Jul ’23US$180.11
US$168.40
-6.5%
14.2%US$220.00US$120.00n/a20
Jun ’23US$134.16
US$160.94
+20.0%
10.8%US$195.00US$120.00n/a18
May ’23US$131.01
US$160.16
+22.2%
10.4%US$191.00US$120.00n/a19
Apr ’23US$148.89
US$158.84
+6.7%
10.9%US$190.00US$120.00n/a19
Mar ’23US$129.46
US$158.84
+22.7%
10.9%US$190.00US$120.00n/a19
Feb ’23US$137.75
US$189.74
+37.7%
12.8%US$254.00US$150.00n/a19
Jan ’23US$154.60
US$190.05
+22.9%
12.7%US$254.00US$150.00n/a19
Dec ’22US$158.25
US$190.05
+20.1%
12.7%US$254.00US$150.00n/a19
Nov ’22US$178.61
US$188.33
+5.4%
13.9%US$254.00US$144.00US$126.6918
Oct ’22US$173.21
US$185.67
+7.2%
15.0%US$254.00US$144.00US$136.8318
Sep ’22US$159.41
US$185.17
+16.2%
15.4%US$254.00US$144.00US$155.9618
Aug ’22US$153.39
US$185.17
+20.7%
15.4%US$254.00US$144.00US$175.4718
Jul ’22US$158.27
US$185.94
+17.5%
16.2%US$254.00US$144.00US$180.1118
Jun ’22US$154.00
US$185.89
+20.7%
16.2%US$254.00US$143.00US$134.1618
May ’22US$143.76
US$184.94
+28.6%
17.0%US$254.00US$138.00US$131.0118
Apr ’22US$143.40
US$188.22
+31.3%
15.8%US$254.00US$138.00US$148.8918
Mar ’22US$152.55
US$190.76
+25.1%
15.0%US$254.00US$138.00US$129.4617
Feb ’22US$162.86
US$198.59
+21.9%
14.2%US$254.00US$138.00US$137.7517
Jan ’22US$175.14
US$199.11
+13.7%
13.9%US$254.00US$138.00US$154.6018
Dec ’21US$177.41
US$198.39
+11.8%
13.8%US$254.00US$138.00US$158.2518
Nov ’21US$166.80
US$198.44
+19.0%
13.9%US$254.00US$138.00US$178.6118

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies